P‐158: Elevated glucocorticoids among victims of intimate partner violence as a biomarker for Alzheimer's disease

Background: Chronic stress has been shown to be a contributing factor to structural changes in the hippocampus and amagdala, and while structural changes of the hippocampus have been associated with an increased risk of Alzheimer’s Disease, no studies have implicated an association between neuroplasticity and atrophy of these brain regions due to emotional and psychological abuse that occurs in intimate partner violence. Objective(s): 1) Determine how chronic stress contributes to structural changes within the hippocampus; 2) Describe the physiological and neurological responses due to exposure to stress hormones; 3) Are structural changes of the hippocampus associated with an increased risk of Alzheimer’s disease; 4) Describe how behavioral and psychophysiological outcomes of intimate partner violence contributes to neuroplasticity; and 5) Provide a systematic review of literature on neural imaging techniques to confirm if glucocorticoids are associated with hippocampal atrophy, and provide evidence that hippocampal atrophy is associated with AD. Methods: Several systematic reviews were conducted. First, on neural imaging techniques on hippocampal atrophy in Alzheimer’s Disease, secondly, on the acute and chronic affects of glucocorticoids on memory, and thirdly the neurobehavioral characteristics of victims of emotional and psychological abuse and those diagnosed with Alzheimer’s Disease. Results: A descriptive analysis from neurobehavioral, physiology, and intimate partner violence literature identified how emotional and psychological abuse among intimate partner violence results in depression, and while neural imaging studies have shown that depression is associated with hippocampal atrophy and hippocampal atrophy is a hallmark of Alzheimer’s Disease. Conclusions: The results of this review suggests by using neural imaging techniques; Positron Emission Tomography can be used to help rule-out Alzheimer’s Disease by hippocampal volume measurement to help reduce misdiagnosis of Alzheimer’s Disease in patients 65 years of age and older and further provides a foundation to support the need to design cognitive behavioral interventions to reduce emotional and psychological abuse. Such interventions can be evaluated and outcomes analyzed to measure efficacy that will ultimately provide a baseline to view Alzheimer’s Disease causality from a multidisciplinary approach and expanding further psychoneuroimmunology research. P-159 VITAMIN B12, APOLIPOPROTEIN E GENOTYPE, AND COGNITIVE PERFORMANCE